Mustang Bio (MBIO) Stock

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial

WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 16,877,638 shares of its common stock having an exercise price of $0.237 per share, originally issued in May 2024. The issuance or resale of the shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-278006). The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $4 million, prior to deducting placement agent fees and offering expenses payable by the Company.

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.

The Mustang Bio stock price closed on a high yesterday, trading at $0.75. The pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13 to $0.75 in a single day.

Penny stock Mustang Bio Inc MBIO shares are trading higher on a strong session volume of 90 million versus an average volume of 3.17 million, as per data from Benzinga Pro.

Mustang Bio (NASDAQ: MBIO ) stock is taking off on Monday after the clinical-stage biopharmaceutical company announced positive results from a study. The recent news includes favorable results from the company's Phase 1.2 clinical trial of MB-106.

Mustang Bio (NASDAQ: MBIO ) stock is taking off on Wednesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 13.9 million shares of MBIO stock changing hands as of this writing.

WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.